RAGE antagonist peptide
RAGE antagonist peptide Basic information
- Product Name:
- RAGE antagonist peptide
- Synonyms:
-
- RAGE antagonist peptide
- L-Leucinamide, N-acetyl-L-α-glutamyl-L-leucyl-L-lysyl-L-valyl-L-leucyl-L-methionyl-L-α-glutamyl-L-lysyl-L-α-glutamyl-
- RAGE antagonist
- RAGE antagonist peptide TFA
- (4S,7S,10S,13S,16S,19S,22S,25S,28S)-28-Acetamido-4-(((S)-1-amino-4-methyl-1-oxopentan-2-yl)carbamoyl)-7,22-bis(4-aminobutyl)-10-(2-carboxyethyl)-16,25-diisobutyl-19-isopropyl-13-(2-(methylthio)ethyl)-6,9,12,15,18,21,24,27-octaoxo-5,8,11,14,17,20,23,26-octaazahentriacontanedioic acid
- CAS:
- 1092460-91-7
- MF:
- C57H101N13O17S
- MW:
- 1272.57
- Mol File:
- 1092460-91-7.mol
RAGE antagonist peptide Chemical Properties
- Boiling point:
- 1608.4±65.0 °C(Predicted)
- Density
- 1.223±0.06 g/cm3(Predicted)
- storage temp.
- Store at -20°C
- solubility
- Soluble in DMSO
- pka
- 4.43±0.10(Predicted)
- form
- Solid
- color
- White to off-white
- Water Solubility
- Soluble to 1 mg/ml in water
- Sequence
- Ac-Glu-Leu-Lys-Val-Leu-Met-Glu-Lys-Glu-Leu-NH2
RAGE antagonist peptide Usage And Synthesis
Uses
RAGE antagonist peptide is an advanced glycation end products (RAGE) antagonist. RAGE antagonist peptide prevents RAGE from binding with several of its most important ligands, including HMGB-1, S100P, and S100A4. RAGE antagonist peptide (RAP) possesses anti-tumor and anti-inflammatory activities[1][2].
in vivo
RAGE antagonist peptide (RAP, 100 μg) inhibits RAGE-mediated Basal NFκB Activity in PDAC cells in vivo[1].
RAGE antagonist peptide (RAP) reduces the growth and metastasis of pancreatic tumors and also inhibited glioma tumor growth[1].
In mice bearing asthma, RAGE antagonist peptide (RAP; 4 mg/kg; i.p.) blunts airway reactivity, airway inflammation and goblet cell metaplasia, and decreases release of Th2 cytokines. RAGE antagonist peptide also reduces total, cytoplasmic and nuclear levels of β-catenin, enhanced β-catenin phosphorylation at Ser33/37/Thr41, which triggers ubiquitination, down-regulated expression of β-catenin targeted genes, and tends to keep β-catenin at the cytomembrane, shifting β-catenin from a signalling active pattern to an adhesive function[2].
| Animal Model: | Cancer cells expressing the NFκB-luc reporter implanted into immune-deficient mice[1]. |
| Dosage: | 100 μg. |
| Administration: | Intratumoral delivery (or intraperitoneally). |
| Result: | Systemic administration caused a substantial reduction (p<0.05) in the NFκB signal 5 h after injection. |
storage
Store at -20°C
References
[1] Thiruvengadam Arumugam, et al. S100P-derived RAGE antagonistic peptide reduces tumor growth and metastasis. Clin Cancer Res. 2012 Aug 15;18(16):4356-64. DOI:10.1158/1078-0432.CCR-12-0221
[2] Lihong Yao, et al. The receptor for advanced glycation end products is required for β-catenin stabilization in a chemical-induced asthma model. Br J Pharmacol. 2016 Sep;173(17):2600-13. DOI:10.1111/bph.13539
RAGE antagonist peptideSupplier
- Tel
- 400-164-7117 13681763483
- product02@bidepharm.com
- Tel
- info@creative-peptides.com
- Tel
- 010-50973130 18101056239
- 3193328036@qq.com
- Tel
- +86-17380623303
- Caroline@youngshechem.com
- Tel
- 0571-87213919
- Eric@peptidego.com